ReviewPLoS pathogens2023
Mechanisms of pathogenicity for the emerging fungus Candida auris.
Review in PLoS pathogens, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.
- Methods for skin load reduction of Candida auris: a systematic review.Antimicrobial resistance and infection control · 2026Pooled it
- Baicalein suppresses adhesion and biofilm formation inMicrobiology spectrum · 2026Article
- Review
- Active Screening forJournal of fungi (Basel, Switzerland) · 2026Review
- The Wor2 phenotypic switching regulator controls biofilm formation in Candida auris.NPJ biofilms and microbiomes · 2026Article
- Invasive Candidiasis in Critically Ill Patients: Fundamental Concepts and Future Directions.Chest · 2026Review
- Article
- Article
- Early Signal Without Clinical Cases: A Single Clade IIIJournal of fungi (Basel, Switzerland) · 2026Article
- Candida auris: a multidimensional focus on its identification, epidemiology, pathogenesis, and therapeutic options.Archives of microbiology · 2026Review
- Article
- Biocide Response of Candida auris.Mycoses · 2026Review
- UnderstandingJournal of medical microbiology · 2026Review
- Outcomes of patients withAntimicrobial stewardship & healthcare epidemiology : ASHE · 2026Article
- Article
- Antifungal Susceptibility and Resistance-Associated Gene Expression in NosocomialJournal of fungi (Basel, Switzerland) · 2025Article
- First report ofMedical mycology case reports · 2025Article
- Risk Factors and Outcomes for Invasive Infection Among Patients Colonized withAntibiotics (Basel, Switzerland) · 2025Article
- Molecular Triggers of Yeast Pathogenicity in the Yeast-Host Interactions.Current issues in molecular biology · 2025Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Candida auris recently emerged as an urgent public health threat, causing outbreaks of invasive infections in healthcare settings throughout the world. This fungal pathogen persists on the skin of patients and on abiotic surfaces despite antiseptic and decolonization attempts. The heightened capacity for skin colonization and environmental persistence promotes rapid nosocomial spread. Following skin colonization, C. auris can gain entrance to the bloodstream and deeper tissues, often through a wound or an inserted medical device, such as a catheter. C. auris possesses a variety of virulence traits, including the capacity for biofilm formation, production of adhesins and proteases, and evasion of innate immune responses. In this review, we highlight the interactions of C. auris with the host, emphasizing the intersection of laboratory studies and clinical observations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.